Clinical Trial Search

Primary: Proportion of Subjects With Lesion Clearance — 16 Participants

Primary: Mean Per Subject Percentage Target Lesions Judged Clear by the Physician's Lesion Assessment (PLA) — 4.82; 26.79; 45.09 percentage of lesions cleared — p=0.0003

Primary: Clearance of SK Lesions — 82 percentage of SK lesion clearance

Primary: Mean of Per Subject Percentages of Target Lesions Judged to be Clear (PWA=0) at Visit 8 — 3.72; 49.5; 57.88 Per-Subject Percent of Lesions Clear

Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants

Primary: Complete Clearance Rate — 16; 15; 10; 12 AK Fields

Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120

Primary: Number of Participants With Suspicious Tumors Detected After Inspection of Problem Area and Inspection of the Full Body. — 810; 631 participants — p=<0.01

Primary: Subject Satisfaction — 21; 14; 4; 0 Participants

Primary: Cure Rate — 751 lesions

Primary: Psoriasis Area and Severity Index (PASI) Score — 3.9 score on a scale

Primary: Mean Change in Physician Lesion Assessment Scale — -0.47; -0.88; -1.12; -0.15 Change in Score on a scale

Primary: Lab* Values of Lesional Area Using Dermoscopy and ImageJ — 68.850; 72.103; 73.147; 72.633 unitless

Primary: Number of Participants Who Experienced an Adverse Event — 472 participants

Primary: To Ascertain the Percentage of Surgical Site Infections Following Excision of Ulcerated Skin Tumours in Dermatology Departments. — 35 Participants

Primary: Mean Change From Baseline to Day 28 in PSS (Psoriasis Severity Score) of the Treatment Target Lesions Compared to Placebo Target Lesions — -1.9; -1.5 PSS score

Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors

Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance

Primary: Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment — 9; 0 Participants

Primary: Overall Subject Satisfaction the Day of Treatment After Daylight Session — 47 Participants

Primary: Number of Responders — 19 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events Related to Clinical Investigation Product During the 30 Days of Follow-up — 2; 3 Participants

Primary: Sensitivity and Specificity — 98.2; 9.5 Ratio * 100 — p=0.05

Primary: Percentage of PLA Responders With Target Lesion Clear (PLA = 0) in Each Arm at Visit 8. — 22; 18; 1 Participants — p=<0.0001

Primary: Rate of Wound Healing — 12.1; 21.3 Days

Primary: Number of Participants Experiencing DLTs (Dose Limiting Toxicities) Based on LSRs (Local Skin Reactions) — 9; 0; 11 Participants

Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 Observations

Primary: Objective Erythema Assessment Using Clinical Grading Analog Scale — 0.8; 0.83; 0.75; 0.29 score on a scale

Primary: Percentage of Grafts Successfully Treated — 78 Percentage of grafts

Primary: Number of Participants That Performed a Skin Self-Examination at 3-months — 161; 185 Participants — p=0.12